# Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)

> **NCT01212094** · PHASE1,PHASE2 · TERMINATED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 44 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Rituximab
- **OTHER:** normal saline

## Key facts

- **NCT ID:** NCT01212094
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 44 (ACTUAL)
- **Why stopped:** The efficacy on CSF biomarkers failed to reach criteria for continuation of the trial
- **Last updated:** 2016-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01212094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01212094, "Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01212094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*